Abstract
Recently, organ support therapy for liver failure has made rapid progress in the direction of clearing bile acids, blood ammonia, and inflammatory factors. However, there is still a lack of high-level evidence-based medicine, necessitating extensive research on the pathogenesis of major subtypes of liver failure so as to explore collaborative key points of clinical research design decisions for appropriate organ support therapy.